

Intellia Therapeutics, Inc. (NTLA)

Nasdaq; healthcare; SIC 2835, In Vitro & In Vivo Diagnostic Substances; CIK 0001652130

Intellia Therapeutics, Inc.

NTLA; healthcare

Grade	E A B C D E weakest fifth of 371 graded peers percentile 87.0; sampling error 2.5 points; lower is stronger
Rank	323 of 371
Profitability	D percentile 77.4
Solvency	C percentile 49.9
Growth and financing	D percentile 62.9
Reliability	0.91 AUC filers with \$591M to \$2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$591M to \$2.67B assets total assets \$842.1M
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	short runway not computable: fortress balance sheet
Inputs computable	7 of 14
Graded from	filings received through Feb 26, 2026 225 days before the rescans; latest periodic filing 10-Q received Aug 6, 2026
Last close	\$12.59 2026-10-08; market equity \$1.8B
Price used in grade	None




E, the bear

weakest fifth of its sector;
letters are fifths of the 371
graded peers

Share price, twelve months to the rescans

split-adjusted close; the letter is fixed at the rescans that set it



NovJanMarMayJulSep

Rescans on file: E from Aug 21, 2026

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only

[illegible]

Business, in the company's words

opening of Item 1 of the 10-K received Feb 26, 2026

Intellia Therapeutics, Inc. ("we," "us," "our," "Intellia," or the "Company") is a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. Our mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, we aim to reset the standard for medicine by durably treating the root causes of disease.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 77.4						
Gross profitability		not computable	32.2%			latest aligned inputs end 2021-12-31; latest annual assets end 2025-12-31
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(1.8%)	(6.6%)	77.4	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 4
Solvency, sleeve percentile 49.9						
Twelve-month failure probability		0.10%	0.07%	58.7	248	2026-06-30
Altman Z double-prime		(6.12)	(0.31)	55.0	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			one or more required annual facts are missing
Current ratio		5.08x	2.96x	36.2	839	2025-12-31
Growth and financing, sleeve percentile 62.9						
Revenue growth, three-year compound		9.1%	10.0%	52.7	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	37.1%			a prior annual working-capital observation is required
Asset growth, three years		(17.9%)	2.1%	80.1	704	2025-12-31
Net share issuance, one year		14.1%	2.5%	55.9	634	2026-02-13


Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Short runway	cash runway is 3.7 months

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
318	Sonoma Pharmaceuticals, Inc. (SNOA)	85.7	E	dilution, fortress balance sheet
319	Outset Medical, Inc. (OM)	85.9	E	dilution
320	National Vision Holdings, Inc. (EYE)	86.2	E	
321	Natural Alternatives International Inc. (NAII)	86.5	E	dilution, late filer, fortress balance sheet
322	DarioHealth Corp. (DRIO)	86.8	E	dilution, short runway
323	Intellia Therapeutics, Inc. (NTLA) <	87.0	E	short runway
324	Heron Therapeutics, Inc. (HRTX)	87.3	E	distress
325	Lexaria Bioscience Corp. (LEXX)	87.6	E	dilution, short runway, distress
326	Intelligent BIO Solutions Inc. (INBS)	87.8	E	dilution, short runway
327	Bristol Myers Squibb Co. (BMY)	88.2	E	
328	Bristol Myers Squibb Co. (CELG-RI)	88.2	E	

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(26.3%)	8.0%	26
Distance from 52-week high	(55.0%)	(31.4%)	21
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	(22.4%)	(1.0%)	21
Book value to price	0.41	0.28	63
Sales to price	0.04	0.31	13
Composite equity issuance, five years	72.7%	20.3%	71
Relative strength against the sector, log excess return	(0.52)	(0.14)	26

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail

Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$106.1M
Operating cash flow, four quarters	-\$346.6M
Months of runway	3.7
Days since last periodic filing	64 (10-Q received Aug 6, 2026)
Median daily dollar volume, 63 sessions	\$45.3M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$33.1M	2021-12-31	2024-02-22	10-K	0000950170-24-018736
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$0	2021-12-31	2022-02-24	10-K	0000950170-22-001981
3	assets	us-gaap:Assets	\$1.3B	2021-12-31	2023-02-23	10-K	0000950170-23-004097
4	net income	us-gaap:NetIncomeLoss	-\$412.7M	2025-12-31	2026-02-26	10-K	0001193125-26-076550
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$394.7M	2025-12-31	2026-02-26	10-K	0001193125-26-076550
6	assets	us-gaap:Assets	\$842.1M	2025-12-31	2026-02-26	10-K	0001193125-26-076550
7	assets	us-gaap:Assets	\$1.2B	2024-12-31	2026-02-26	10-K	0001193125-26-076550
8	current assets	us-gaap:AssetsCurrent	\$527.7M	2025-12-31	2026-02-26	10-K	0001193125-26-076550
9	current liabilities	us-gaap:LiabilitiesCurrent	\$103.9M	2025-12-31	2026-02-26	10-K	0001193125-26-076550
10	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$2.6B	2025-12-31	2026-02-26	10-K	0001193125-26-076550
11	operating income	us-gaap:OperatingIncomeLoss	-\$441.0M	2025-12-31	2026-02-26	10-K	0001193125-26-076550
12	book equity	us-gaap:StockholdersEquity	\$671.4M	2025-12-31	2026-02-26	10-K	0001193125-26-076550
13	liabilities	us-gaap:Liabilities	\$170.7M	2025-12-31	2026-02-26	10-K	0001193125-26-076550
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$67.7M	2025-12-31	2026-02-26	10-K	0001193125-26-076550
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$57.9M	2024-12-31	2026-02-26	10-K	0001193125-26-076550
16	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$36.3M	2023-12-31	2026-02-26	10-K	0001193125-26-076550
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$52.1M	2022-12-31	2025-02-27	10-K	0000950170-25-029007
18	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$1.1M	2025-12-31	2026-02-26	10-K	0001193125-26-076550
19	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$348.9M	2024-12-31	2026-02-26	10-K	0001193125-26-076550
20	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$5.8M	2024-12-31	2026-02-26	10-K	0001193125-26-076550
21	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$394.1M	2023-12-31	2026-02-26	10-K	0001193125-26-076550
22	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$14.0M	2023-12-31	2026-02-26	10-K	0001193125-26-076550
23	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$333.3M	2022-12-31	2025-02-27	10-K	0000950170-25-029007
24	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$13.6M	2022-12-31	2025-02-27	10-K	0000950170-25-029007
25	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$6.2M	2016-12-31	2019-02-27	10-K	0001564590-19-004680
26	depreciation amortization	us-gaap:Depreciation	\$1.1M	2016-12-31	2018-03-14	10-K	0001564590-18-005544
27	operating income	us-gaap:OperatingIncomeLoss	-\$32.2M	2016-12-31	2019-02-27	10-K	0001564590-19-004680
28	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$11.6M	2016-12-31	2018-03-14	10-K	0001564590-18-005544
29	income tax	us-gaap:IncomeTaxExpenseBenefit	\$0	2016-12-31	2017-03-14	10-K	0001193125-17-082186
30	current assets	us-gaap:AssetsCurrent	\$281.3M	2016-12-31	2018-03-14	10-K	0001564590-18-005544
31	current liabilities	us-gaap:LiabilitiesCurrent	\$30.7M	2016-12-31	2018-03-14	10-K	0001564590-18-005544
32	assets	us-gaap:Assets	\$1.3B	2023-12-31	2025-02-27	10-K	0000950170-25-029007
33	assets	us-gaap:Assets	\$1.5B	2022-12-31	2024-02-22	10-K	0000950170-24-018736
34	shares outstanding	dei:EntityCommonStockSharesOutstanding	118,133,546	2026-02-13	2026-02-26	10-K	0001193125-26-076550
35	shares outstanding	dei:EntityCommonStockSharesOutstanding	103,517,460	2025-02-14	2025-02-27	10-K	0000950170-25-029007